John Koren III
Assistant Research Professor, Department of Chemistry and Biochemistry, Director of Biological Screening and Development, Warren Family Research Center for Drug Discovery and Development
University of Notre Dame
Oncogenic mutations alter the survival mechanisms of cancer cells. The diminished capacity of a cancer cell to undergo apoptosis limits the efficacy of targeted therapeutic strategies and increases the probability of refractory and resistant cancer cell populations. The focus of the Koren Lab is to identify and profile the ‘survival addictions’ of individual cancer cells. Once profiled, we generate distinct and personalized combination therapeutic strategies to enhance the effect of targeted therapeutics by ablating the survival addictions unique to a cancer cell population.
In addition to cancer biology, the Koren Lab studies the molecular mechanisms and physiological outcomes of protein aggregation in neurodegenerative disorders, including Alzheimer’s Disease, Amyotrophic Lateral Sclerosis, and Parkinson’s Disease. We study the role of molecular chaperones, the cellular ‘quality control’ system, in neurodegenerative diseases, glaucoma, mental health disorders, and rare diseases such as Neimann-Pick Type C and Bechet’s.